Payment overview · 2025
General Payments
$1,000.74
50 reported records · 14 companies
Healthcare provider profile · identity verified
Brian L. Hunter, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · HAROLD, KY · NPI 1811976616
Verified facts
What the public records show
CMS Open Payments records show Brian L. Hunter, P.A. received $1,000.74 in general payments during 2025 across 50 reported records.
Novartis Pharmaceuticals Corporation accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Leqvio, Mounjaro, Nurtec Odt, Ozempic, Qulipta, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 461 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LEQVIO as an associated drug or biological on 126702 records involving 33819 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Leqvio by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LITFULO as an associated drug or biological on 44294 records involving 9534 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Litfulo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $270.41 | 27.0% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $243.32 | 24.3% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $122.38 | 12.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.57 | 7.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.23 | 4.9% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $42.86 | 4.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.76 | 3.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.10 | 3.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.28 | 3.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.75 | 2.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.14 | 2.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.43 | 1.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.19 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.32 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,000.74 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $270.41 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $243.32 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $124.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $122.38 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $94.78 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.57 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.23 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.23 | 3 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $42.86 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.10 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.28 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.75 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 210 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 102 | exact normalized | Medicare Part D |
| LEQVIO leqvio |
2025 | Leqvio | 2024 | 87 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 461 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
90 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
210 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
461 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | LEQVIO open payments reported associated product |
CMS Open Payments — General Payments 126702 supporting records · 33819 recipient NPIs · example record 1200004747 |
Leqvio · 2024 Exact normalized brand match · 1 Part D row |
87 | 58 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | LITFULO open payments reported associated product |
CMS Open Payments — General Payments 44294 supporting records · 9534 recipient NPIs · example record 1228794292 |
Litfulo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mounjaro | Tirzepatide | 461 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 443 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 426 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 359 | 67 |
| Famotidine | Famotidine | 357 | 61 |
| Lisinopril | Lisinopril | 342 | 68 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 280 | 49 |
| Montelukast Sodium | Montelukast Sodium | 276 | 35 |
| Furosemide | Furosemide | 260 | 57 |
| Omeprazole | Omeprazole | 256 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 39 |
| Ibuprofen | Ibuprofen | 233 | 56 |
| Ondansetron Hcl | Ondansetron Hcl | 215 | 52 |
| Farxiga | Dapagliflozin Propanediol | 210 | 46 |
| Potassium Chloride | Potassium Chloride | 208 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 200 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 38 |
| Gabapentin | Gabapentin | 187 | 31 |
| Azithromycin | Azithromycin | 181 | 121 |
| Meloxicam | Meloxicam | 179 | 33 |
| Sucralfate | Sucralfate | 179 | 40 |
| Amoxicillin | Amoxicillin | 167 | 111 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 38 |
| Simvastatin | Simvastatin | 161 | 28 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 157 | 34 |
| Losartan Potassium | Losartan Potassium | 151 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 147 | 29 |
| Metformin Hcl | Metformin Hcl | 146 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 145 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 22 |
| Celecoxib | Celecoxib | 136 | 25 |
| Prednisone | Prednisone | 135 | 88 |
| Amitriptyline Hcl | Amitriptyline Hcl | 131 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 20 |
| Irbesartan | Irbesartan | 111 | 23 |
| Jardiance | Empagliflozin | 102 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 18 |
| Baclofen | Baclofen | 101 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 95 | 23 |
| Allopurinol | Allopurinol | 92 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 13 |
| Linzess | Linaclotide | 90 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 15 |
| Leqvio | Inclisiran Sodium | 87 | 58 |
| Valsartan | Valsartan | 85 | 20 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 84 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 82 | 21 |
| Sertraline Hcl | Sertraline Hcl | 82 | 13 |
| Fluconazole | Fluconazole | 79 | 43 |
| Fenofibrate | Fenofibrate Nanocrystallized | 76 | 12 |
| Ondansetron Odt | Ondansetron | 75 | 28 |
| Carvedilol | Carvedilol | 71 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 71 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 14 |
| Glyburide | Glyburide | 70 | 15 |
| Nitroglycerin | Nitroglycerin | 70 | 25 |
| Glipizide | Glipizide | 69 | 13 |
| Eliquis | Apixaban | 67 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 12 |
| Spironolactone | Spironolactone | 63 | 11 |
| Pregabalin | Pregabalin | 61 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | suppressed |
| Bumetanide | Bumetanide | 59 | 11 |
| Methylprednisolone | Methylprednisolone | 59 | 40 |
| Cefdinir | Cefdinir | 57 | 42 |
| Bupropion Xl | Bupropion Hcl | 55 | 11 |
| Ezetimibe | Ezetimibe | 54 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 40 |
| Metformin Hcl Er | Metformin Hcl | 51 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 12 |
| Topiramate | Topiramate | 49 | suppressed |
| Constulose | Lactulose | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 38 |
| Ozempic | Semaglutide | 47 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Cilostazol | Cilostazol | 43 | 11 |
| Finasteride | Finasteride | 43 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 41 | 12 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Estradiol | Estradiol | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | 15 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Piroxicam | Piroxicam | 36 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 35 | 23 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Diazepam | Diazepam | 34 | 13 |
| Emgality Syringe | Galcanezumab-Gnlm | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 15 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 29 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Testosterone | Testosterone | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Edarbi | Azilsartan Medoxomil | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Theophylline Er | Theophylline Anhydrous | 20 | suppressed |
| Ubrelvy | Ubrogepant | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Litfulo | Ritlecitinib Tosylate | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Diflunisal | Diflunisal | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,000.74 · 50 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, AJOVY, CAPLYTA, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error